| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2020 | MATTEK CORP | 200 HOMER AVE | ASHLAND | MA | 01721-1717 | MIDDLESEX | USA | R43ES032363 | Organotypic Culture Models (OCM) developed from experimental animals for Chemical Toxicity Screening. | 000 | 1 | NIH | 4/6/2023 | $0 |
| | 2023 | 2019 | MATTEK CORP | 200 HOMER AVE | ASHLAND | MA | 01721-1717 | MIDDLESEX | USA | R43ES031044 | Organotypic Rat Tissue Models for Translational Toxicity Assessments | 000 | 1 | NIH | 11/8/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2019 | MATTEK CORPORATION | 200 HOMER AVE | ASHLAND | MA | 01721-1717 | MIDDLESEX | USA | U44ES014312 | Validation of an In Vitro Human Airway Model for Regulatory Toxicity Testing | 000 | 6 | NIH | 1/18/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2019 | MATTEK CORPORATION | 200 HOMER AVE | ASHLAND | MA | 01721-1717 | MIDDLESEX | USA | R43ES030648 | Novel Approach for Characterizing Exposure and Response to Engineered Nanomaterials in the Gut | 000 | 1 | NIH | 1/31/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $252,129 ) |
| | 2020 | 2020 | MATTEK CORPORATION | 200 HOMER AVE | ASHLAND | MA | 01721-1717 | MIDDLESEX | USA | R43ES032363 | Organotypic Culture Models (OCM) developed from experimental animals for Chemical Toxicity Screening. | 001 | 1 | NIH | 9/16/2020 | $0 |
| | 2020 | 2020 | MATTEK CORPORATION | 200 HOMER AVE | ASHLAND | MA | 01721-1717 | MIDDLESEX | USA | R43ES032363 | Organotypic Culture Models (OCM) developed from experimental animals for Chemical Toxicity Screening. | 000 | 1 | NIH | 8/20/2020 | $252,129 |
| | 2020 | 2019 | MATTEK CORPORATION | 200 HOMER AVE | ASHLAND | MA | 01721-1717 | MIDDLESEX | USA | U44ES014312 | Validation of an In Vitro Human Airway Model for Regulatory Toxicity Testing | 000 | 6 | NIH | 11/6/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $690,297 ) |
| | 2019 | 2019 | MATTEK CORPORATION | 200 HOMER AVE | ASHLAND | MA | 01721-1717 | MIDDLESEX | USA | U44ES014312 | Validation of an In Vitro Human Airway Model for Regulatory Toxicity Testing | 000 | 6 | NIH | 3/22/2019 | $241,361 |
| | 2019 | 2019 | MATTEK CORPORATION | 200 HOMER AVE | ASHLAND | MA | 01721-1717 | MIDDLESEX | USA | R43ES030648 | Novel Approach for Characterizing Exposure and Response to Engineered Nanomaterials in the Gut | 000 | 1 | NIH | 4/17/2019 | $225,000 |
| | 2019 | 2019 | MATTEK CORPORATION | 200 HOMER AVE | ASHLAND | MA | 01721-1717 | MIDDLESEX | USA | R43ES031044 | Organotypic Rat Tissue Models for Translational Toxicity Assessments | 000 | 1 | NIH | 9/19/2019 | $223,936 |
| | 2019 | 2018 | MATTEK CORPORATION | 200 HOMER AVE | ASHLAND | MA | 01721-1717 | MIDDLESEX | USA | R44GM108164 | An In Vitro Human Small Intestine Tissue Model for Drug Permeation Studies | 000 | 4 | NIH | 5/16/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $703,944 ) |
| | 2018 | 2018 | MATTEK CORPORATION | 200 HOMER AVE STE 200 | ASHLAND | MA | 01721-1717 | MIDDLESEX | USA | U44ES014312 | Validation of an In Vitro Human Airway Model for Regulatory Toxicity Testing | 000 | 5 | NIH | 2/28/2018 | $530,965 |
| | 2018 | 2018 | MATTEK CORPORATION | 200 HOMER AVE STE 200 | ASHLAND | MA | 01721-1717 | MIDDLESEX | USA | R44GM108164 | An In Vitro Human Small Intestine Tissue Model for Drug Permeation Studies | 000 | 4 | NIH | 1/8/2018 | $172,979 |
|
| Issue Date FY: 2017 ( Subtotal = $939,014 ) |
| | 2017 | 2017 | MATTEK CORPORATION | 200 HOMER AVE STE 200 | ASHLAND | MA | 01721-1717 | MIDDLESEX | USA | R44GM108164 | An In Vitro Human Small Intestine Tissue Model for Drug Permeation Studies | 000 | 3 | NIH | 1/6/2017 | $507,987 |
| | 2017 | 2017 | MATTEK CORPORATION | 200 HOMER AVE STE 200 | ASHLAND | MA | 01721-1717 | MIDDLESEX | USA | U44ES014312 | Validation of an In Vitro Human Airway Model for Regulatory Toxicity Testing | 000 | 4 | NIH | 2/28/2017 | $431,027 |
|
| Issue Date FY: 2016 ( Subtotal = $648,815 ) |
| | 2016 | 2016 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | R44GM108164 | An In Vitro Human Small Intestine Tissue Model for Drug Permeation Studies | 000 | 2 | NIH | 1/27/2016 | $648,815 |
|
| Issue Date FY: 2014 ( Subtotal = $440,284 ) |
| | 2014 | 2014 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | R21AI104385 | Use of a CB2 Ligand to prevent HIV-1 Infection and Transmission | 000 | 2 | NIH | 5/19/2014 | $221,953 |
| | 2014 | 2014 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | R43GM108164 | An In Vitro Human Small Intestine Tissue Model for Drug Permeation Studies | 000 | 1 | NIH | 6/20/2014 | $218,331 |
|
| Issue Date FY: 2013 ( Subtotal = $1,072,239 ) |
| | 2013 | 2013 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | R21AI104385 | Use of a CB2 Ligand to prevent HIV-1 Infection and Transmission | 001 | 1 | NIH | 9/6/2013 | $8,516 |
| | 2013 | 2013 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | R44ES015641 | VALIDATION OF HUMAN VAGINAL TISSUE ASSAY FOR ENDOCRINE DISRUPTORS | 000 | 4 | NIH | 12/11/2012 | $189,035 |
| | 2013 | 2013 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | R21AI104385 | Use of a CB2 Ligand to prevent HIV-1 Infection and Transmission | 000 | 1 | NIH | 6/14/2013 | $209,883 |
| | 2013 | 2013 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | R44ES020074 | HUMAN CORNEAL MODEL FOR OCULAR IRRITATION ASSAY | 000 | 4 | NIH | 12/20/2012 | $181,578 |
| | 2013 | 2013 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | R44GM084551 | GENETICALLY MODIFIED TISSUE ENGINEERED IN VITRO HUMAN MODELS | 000 | 3 | NIH | 4/19/2013 | $483,227 |
|
| Issue Date FY: 2012 ( Subtotal = $1,872,246 ) |
| | 2012 | 2012 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | R44ES014312 | VALIDATION OF AN IN VITRO HUMAN AIRWAY MODEL | 000 | 3 | NIH | 1/11/2012 | $537,491 |
| | 2012 | 2012 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | R44ES020074 | HUMAN CORNEAL MODEL FOR OCULAR IRRITATION ASSAY | 000 | 3 | NIH | 1/11/2012 | $390,762 |
| | 2012 | 2012 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | R44GM084551 | GENETICALLY MODIFIED TISSUE ENGINEERED IN VITRO HUMAN MODELS | 000 | 2 | NIH | 5/4/2012 | $483,227 |
| | 2012 | 2012 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | R44ES015641 | VALIDATION OF HUMAN VAGINAL TISSUE ASSAY FOR ENDOCRINE DISRUPTORS | 000 | 3 | NIH | 2/3/2012 | $460,766 |
|
| Issue Date FY: 2011 ( Subtotal = $1,175,724 ) |
| | 2011 | 2011 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | R44ES015641 | VALIDATION OF HUMAN VAGINAL TISSUE ASSAY FOR ENDOCRINE DISRUPTORS | 000 | 2 | NIH | 12/21/2010 | $327,839 |
| | 2011 | 2011 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | R44ES020074 | HUMAN CORNEAL MODEL FOR OCULAR IRRITATION ASSAY | 000 | 2 | NIH | 12/29/2010 | $352,177 |
| | 2011 | 2011 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | R44HD050023 | VALIDATION OF A HUMAN IN VITRO VAGINAL IRRITATION TEST | 000 | 4 | NIH | 9/12/2011 | $197,217 |
| | 2011 | 2011 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | R44ES014312 | VALIDATION OF AN IN VITRO HUMAN AIRWAY MODEL | 000 | 2 | NIH | 12/29/2010 | $298,491 |
|
| Issue Date FY: 2010 ( Subtotal = $2,249,634 ) (Continued on the next page) |
| | 2010 | 2010 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | R44AR052982 | IN VITRO TISSUE MODEL OF PSORIASIS | 000 | 3 | NIH | 8/19/2010 | $436,471 |
| | 2010 | 2010 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | R43GM093563 | IN VITRO HUMAN TISSUE MODEL FOR INTRAVAGINAL DRUG DELIVERY | 000 | 1 | NIH | 9/6/2010 | $267,914 |
| | 2010 | 2010 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | U01AI070914 | VAGINAL/CERVICAL TISSUE MODELS: ENDOCRINE EFFECTS AND SUSCEPTIBILITY TO INFECTION | 000 | 5 | NIH | 8/25/2010 | $619,724 |
| | 2010 | 2010 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | R44HD050023 | VALIDATION OF A HUMAN IN VITRO VAGINAL IRRITATION TEST | 001 | 3 | NIH | 9/1/2010 | $491,867 |
| | 2010 | 2010 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721-1716 | MIDDLESEX | USA | R44ES015002 | RECONSTRUCTED SKIN MICRONUCLEUS GENOTOXICITY ASSAY | 000 | 3 | NIH | 8/13/2010 | $433,658 |
| | 2010 | 2009 | MATTEK CORPORATION | 200 HOMER AVENUE | ASHLAND | MA | 01721 | MIDDLESEX | USA | R44HD050023 | VALIDATION OF A HUMAN IN VITRO VAGINAL IRRITATION TEST | 000 | 2 | NIH | 7/1/2010 | $0 |
|
